A clinical trial in which volunteers were infected with dengue virus six months after receiving either an experimental dengue vaccine developed by scientists from the National Institutes of Health (NIH) or a placebo injection yielded starkly contrasting results. All 21 volunteers who received the vaccine, TV003, were protected from infection, while all 20 placebo recipients developed infection. The study, published in Science Translational Medicine, underscores the importance of human challenge studies, in which volunteers are exposed to disease-causing pathogens under carefully controlled conditions.
OSAP Disclaimer | Please notify our webmaster of any problems with this website. OSAP thanks its Super Sponsors for their support in 2016. Sponsorship does not imply endorsement by OSAP of a company's products or services.